Possession of the apolipoprotein E (APOE) ε4 allele is the most frequently associated genetic susceptibility factor for Alzheimer's disease (AD). Recently, new polymorphisms in the regulatory region of the APOE gene have been described. We analysed the effects of three of these mutations (-491 AT, -427 CT and Th1/E47cs) on disease risk in a large case-control study, and tested their impacts on APOE allelic expression in brain tissues. The Th1/E47cs T allele was associated with an increased risk of occurrence of AD, while the -491 T allele was associated with a decreased risk, independently of the APOE ε2/ε3/ε4 polymorphism effect. However, the impact of the Th1/E47cs mutation was the strongest. The -427 CT polymorphism was not associated with the disease. In AD subjects heterozygous for the ε4 allele, analysis of allelic expression showed that the relative expression levels of the ε4 allele were higher than those of the corresponding controls. Consistent with epidemiological data, the relative level of expression of the ε4 allele was modified accordingly to the presence or absence of the two main promoter polymorphisms, indicating, in vivo, the deleterious effect of the Th1/E47cs T allele and the protective effect of the -491 T allele in population.
INTRODUCTION
The presence of at least one apolipoprotein E (APOE) ε4 allele is a major genetic susceptibility factor for late-onset familial and sporadic Alzheimer's disease (AD). This risk factor accounts for ∼45-60% of cases (1) . Indeed, the ε4 allele is associated with an increased risk of AD in an allele dose dependant manner (2, 3) . Conversely, the ε2 allele protects against the disease (4, 5) . The mechanisms by which apoE isoforms are implicated in human nervous system physiology and influence the pathogenesis of AD, are not fully understood (2, (6) (7) (8) . The effect of the APOE ε2/ε3/ε4 alleles may not be due only to the intrinsic biochemical properties of the isoforms coded by these alleles. Other genetic variants influencing APOE allele expression may account for the increase or decrease in the level of risk of AD. This hypothesis is supported firstly by preliminary observations of the relative overexpression of the ε4 allele compared with the ε3 allele in the brain of patients with AD, compared with controls (9) . Secondly, Th1/E47cs and -491 AT polymorphisms located in the APOE promoter have been described and associated with AD risk *To whom correspondence should be addressed. Tel: +33 3 20 87 72 28; Fax: + 33 3 20 87 78 94; Email: marie-christine.chartier@pasteur-lille.fr (10, 11) . Moreover the effect of these two polymorphisms on AD occurrence was described separately in case-control studies. This prompted us to analyse the relative contribution of these two promoter polymorphisms, and also a third, located at position -427 of the APOE promoter together with the ε2/ε3/ε4 alleles, towards AD risk in a large case-control study (509 controls and 573 AD cases). Furthermore, we investigated the possible influences of the two main polymorphisms on APOE ε2/ε3/ε4 allelic relative expression in brain tissues, to approach their in vivo functionality, in brain samples from 49 AD cases and 45 controls.
RESULTS
As expected, possession of the ε4 allele was strongly associated with AD [odds ratio (OR) = 5.40; 95% confidence interval (CI): 4.11-7.09, P < 0.0001], while the presence of the ε2 allele exhibited a protective effect (OR = 0.47; 95% CI: 0.31-0.70, P = 0.0003). The frequency of the Th1/E47cs T allele was increased in AD cases compared with controls (χ 2 = 23.1, P < 0.0001; Table 1 ). The risk of developing AD for carriers of at least one T allele was 2.13 (95% CI: 1.61-2.83). Conversely, the frequency of the -491 T allele was decreased in patients, compared with controls (χ 2 = 9.5, P = 0.002). The genotype and allele frequencies of the -491 AT polymorphism were both similar to those observed in the North American population but differed from the Spanish sample (11) . The OR to develop AD in subjects bearing at least one -491 T allele was 0.67 (95% CI: 0.52-0.88, P = 0.004). No association with the disease was detected for the -427 CT polymorphism. To eliminate possible confounding effects of the APOE ε4 allele on the association of the Th1/E47cs and -491 AT polymorphisms with AD, we controlled the effects of each allele using logistic regression adjusted for the presence or absence of the ε4 allele. After adjustment, the risk associated with possession of at least one Th1/E47cs T allele persisted (OR = 1.56; 95% CI: 1.15-2.11, P = 0.004), while the risk associated with -491 T allele did not (OR = 0.82; 95% CI: 0.62-1.10, P = 0.19). This observation suggested that the effect of the Th1/E47cs T allele is independent of that of the ε4 allele, while the -491 T allele is not. However, since the Th1/E47cs G and ε2 alleles are in complete disequilibrium (Table  2) , we also performed a logistic regression including both protective and deleterious effects of ε2 and ε4 alleles, respectively. The risk associated with the Th1/E47cs T allele still persisted (OR = 1.41; 95% CI: 1.03-1.92, P = 0.03).
If we assume that the level of expression of the APOE alleles is increased or decreased due to cis mutations in the promoter region, this hypothesis has two major implications: (i) promoter mutations may modulate the expression of the APOE alleles leading to an increase or decrease of the deleterious or protective risk associated with the ε4 or ε2 allele, respectively; and (ii) given that what determines the risk is the importance of the relative level of expression of both alleles of APOE, as suggested by preliminary data (12) , the promoter mutations will have differential effects detectable mainly in APOE ε2/ε3/ε4 heterozygous individuals. To verify these assumptions, we studied the OR of developing AD for APOE heterozygous and homozygous individuals, using logistic regression adjusted for age, sex and the presence of at least one -491 T and one Th1/E47 T allele. In APOE ε2/ε3/ε4 homozygotes, no effect was found (OR = 1.13; 95% CI: 0.77-1.65, and OR = 0.99; 95% CI: 0.68-1.44, for Th1/E47 T and -491 T alleles, respectively). Conversely, in APOE ε2/ε3/ε4 heterozygotes, individuals bearing at least one Th1/E47 T allele had an increased risk of developing AD (OR = 3.57; 95% CI: 2.22-5.75, P < 0.0001), while individuals bearing at least one -491 T allele exhibited a protective effect (OR = 0.57; 95% CI: 0.37-0.90, P = 0.014), consistent with our initial hypothesis. a Three individuals were ε2/ε2 in control. The -491 A and ε4 alleles present a degree of linkage disequilibrium of 26 and 75% in control and AD populations, respectively. The Th1/E47cs G and ε2 alleles are in complete linkage disequilibrium in both populations, while the Th1/E47cs T and ε4 alleles show a linkage disequilibrium of 44% in both populations. No linkage disequilibrium was found between -491 AT and Th1/E47cs polymorphisms.
The location of both polymorphisms within the regulatory region of the APOE gene, and their potential effect in vitro reported in hepatoma cells, suggested that these polymorphisms may play a role in the control of APOE expression levels in brain. In order to test this hypothesis, we obtained 94 AD or control brain tissues heterozygous for the APOE and measured the percentage of the expression level of the three APOE alleles. In controls, the ε4 allele was strongly underexpressed compared with the ε3 or the ε2 allele in the ε3ε4 and ε2ε4 brain samples, respectively, while the ε2 and ε3 expressions were almost similar in the ε2ε3 samples (Fig. 1) . As suggested by preliminary data (9), there was a clear and consistent increase in the relative ε4 allelic expression between ε3ε4 patients and ε3ε4 controls (34.9 ± 2.7 versus 22.9 ± 2.4%, respectively, P < 10 -4 ). A significant decrease in the relative ε2 expression was demonstrated in ε2ε3 AD brains compared with ε2ε3 controls (32.8 ± 4.5 versus 47.8 ± 3.9%, respectively, P = 0.002). An increased expression of the ε4 allele was also detected between the ε2ε4 AD and controls (46.0 ± 5.4 versus 28.0 ± 2.8%, respectively, P = 0.01). Measured values in ε2ε4 AD cases and controls corresponded to the expected values estimated from the other genotypes reinforcing our observations (see Materials and Methods; arrows in Fig. 1) .
The previous epidemiological data suggest that the -491 AT polymorphism and the Th1/E47cs polymorphism may be good candidates to mediate these allelic distortions. In particular, estimation of the OR associated with the combination of the ε4 and the Th1/E47cs T allele on the same chromosome indicate an estimated increased risk of 1.7 for the heterozygous ε3/ε4 individuals presenting this haplotype, as described previously (10) . Thus, if the ε4 allele is associated with the Th1/E47cs T allele on the same chromosome, while the ε3 allele is associated with the Th1/E47cs G allele on the other, the relative ε4/ε3 mRNA ratio should be significantly increased and associated with AD. Conversely, if both ε4 and ε3 alleles are under the control of the same Th1/E47cs allele, either G or T, the level of expression should be similar. Thus, we expected a stronger distortion in Th1/E47cs heterozygotes than in homozygotes. This argument is clearly illustrated by our experimental data ( Table 3) . The same approach is valid for the -491 AT mutation.
The influence of both polymorphisms on relative mRNA expression level could be observed only in cases ( Fig. 2 and Table  3 ). Affected patients carrying the Th1/E47cs GT or the -491 AT genotypes had the highest and lowest relative levels of expression of ε4 expression, respectively ( Fig. 1 and Table 3 ). The difference in the levels of expression in cases was more pronounced for the Th1/E47cs GT bearers than for the -491 AT bearers (36.6 ± 2.2 versus 33.5 ± 1.3%, respectively, P = 0.004; Fig. 2 ).
DISCUSSION
The deleterious effect of the Th1/E47cs T allele and the protective effect of the -491 T allele described recently (10, 11) were confirmed by this large case-control study. These effects were obvious in the APOE heterozygous population, but not in the homozygous population. These data are not surprising for two reasons: (i) we would expect that APOE ε4 homozygotes with high expressing promoter alleles on both chromosomes, had a higher risk of developing AD than ε4 homozygotes with low expressing promoter alleles. However, the small size of the ε4/ε4 control population did not allow such an impact to be brought forward; (ii) as a consequence, the measured OR in ε2/ε3/ε4 homozygous individuals mainly depended on the ε3/ε3 population. No effect was found in the latter population whatever the studied promoter polymorphism. Furthermore, the apoE3 isoform is considered as the isoform having the lesser effect on AD pathology. We did not confirm the deleterious effect of the -491 AA genotype described in the ε3ε3 Spanish population (11) . This discrepancy may be explained by the significant difference in the -491 AT genotype distribution observed between the Spanish and the French or American control populations. Since the AD genotypic frequency was similar in the three studied populations, the deleterious effect of the AA genotype in the ε3ε3 group may only be due to the distribution in the Spanish control population.
When the impacts of these two promoter polymorphisms and the APOE ε4 allele were studied simultaneously in a multiple logistic regression model, we demonstrated that only the Th1/E47cs T allele modified the risk of developing AD independently of the ε4 allele, suggesting that the -491 polymorphisms may play a weaker role compared with Th1/E47cs in the development of AD. The location of both polymorphisms in the regulatory region of the APOE gene, their effects on the transcriptional activity in hepatoma cells (12) and their impacts in AD population, prompted us to test the hypothesis that they may modulate the APOE expression levels in brain and, therefore, be partly responsible for the marked allelic distortion of the APOE mRNA we observed in AD brain compared with controls in all the heterozygous genotypes. Indeed, the ε4 allele was overexpressed in ε3ε4 and ε2ε4 AD cases and the ε2 allele underexpressed in ε2ε3 AD cases compared with their respective controls. Consistent with the effects deduced from the case-Human Molecular Genetics, 1998 , Vol. 7, No. 9 1515 control study, the ε4 allele expression in AD brain was also correlated with the polymorphisms of the regulatory region of the APOE (Fig. 2) : the Th1/E47cs T allele may increase the relative expression of the ε4 allele in AD, while the -491 T allele may decrease it.
Because numerous studies reported contradictory findings in brain and cerebrospinal fluid (CSF) concerning apoE protein level, it is difficult to speculate on the link between APOE mRNA and apoE protein levels (13) (14) (15) (16) (17) . However, as suggested by Yamada et al., the APOE expression may be decreased by an ε4 gene dosage in AD: the ε3 homozygous AD cases expressed more APOE mRNA than the ε4ε4 AD cases, the ε3ε4 presenting an intermediate mRNA level (18) . A similar trend was found for proteins in AD brains (14) or in plasma (J. Poirier, personal communication), indicating that both the protein and mRNA levels may be directly correlated during the disease. Underlining the importance of apoE level, the APOE expression has been shown to correlate with Aβ peptide deposition in transgenic mice (19, 20) .
This observation may be very important, since previous reports showed that the APOE gene expression was increased between 2-and 3-fold in AD brains compared with controls regardless of the APOE genotype (18, 21) . In ε3ε4 AD cases, both the ε3 and ε4 alleles would be overexpressed, but the ε4 allele, due to the promoter mutations, being still more overexpressed than the ε3 allele. Exacerbation of APOE ε4 expression level may foster the intrinsic deleterious effect of the apoE4 isoform in AD for instance in promoting Aβ aggregation (2, 6, 22) .
This expression level modulation may be intended not only for neurodegenerative disease, but also for neural development. Indeed, we observed a strong underexpression of the ε4 allele compared with the ε3 allele in controls. Although the role of apoE during maturation and ageing is not completely understood yet, the fact that apoE deficient homozygous mice exhibit reversible dendritic alterations and significant learning deficits in the Morris water maze, suggests neurotrophic capabilities for apoE (23) (24) (25) . However, the abilities of each isoform may be different since the apoE4 isoform does not have the same effects as the apoE3 isoform on neurite outgrowth (26) . For instance, apoE3, but not apoE4, may stabilize the neuronal cytoskeleton (7) .
A global assessment of the modulation of APOE expression is difficult. Indeed, to date, five polymorphisms have been described in the APOE promoter region (10, 12) . Two of the three polymorphisms studied, seem to play a role in AD. The two remaining have allelic frequencies <1% (12) , and therefore cannot explain the effects observed in the case-control and mRNA studies. However, it remains possible that other unknown polymorphisms modulate the APOE mRNA level. These new mutations may be far away from the promoter polymorphisms, for instance in the brain tissue specific element (27, 28) . The interaction between all the putative polymorphisms modifying APOE expression will be very difficult to model. Various combinations of different mutations may confer a large APOE expression heterogeneity at two levels: (i) the absolute level of APOE expression and (ii) the percentage of expression of one allele compared with the other in heterozygous individuals, adding to the complexity of the association between APOE and AD. Therefore, the variation of the APOE expression induced by the APOE promoter polymorphisms may partly explain the heterogeneity of the impact of the ε4 allele in different ethnic groups (1, 29) .
MATERIALS AND METHODS

Populations
The AD and control samples were Caucasians originating from France. Diagnoses of probable AD were established according to the DSM-III-R and NINDCS-ADRDA criteria (n = 573; age = 73.8 ± 8.1 years; age of onset = 70.4 ± 7.9 years; 35.9% of men) (30, 31) . The Caucasian controls were defined as subjects without DMS-III-R dementia criteria and with integrity of their cognitive functions (n = 509; age = 74.3 ± 9.9 years; 35.9% of men). Each individual or their relatives signed an informed consent.
Brain samples
These consisted of 45 controls (age = 80.3 ± 8.6 years; 44.9% of men) and 49 late-onset AD cases (age = 76.5 ± 9.3 years; age of onset = 68.4 ± 10.0 years; 44.4% of men), selected according to their APOE genotype. Eighty-eight samples were extracted from frontal cortex and six from occipital cortex, no difference of relative expressions being observed between those regions. The mean age was 78.4 ± 8.7 years for the AD cases genotyped ε3ε4 and 75.9 ± 7.5 years for the controls. Diagnoses were confirmed by neuropathological examination.
Genotype
The -491 AT, -427 CT, Th1E47cs and APOE genotypes were produced by PCR followed by restriction enzyme digestion of the amplified DNA as described (10) (11) (12) 32) .
APOE allelic quantitation
Total RNA extraction from brain tissues, heterozygous for APOE genotype, was performed as described (33) or using RNeasy Mini kit (Qiagen, Germany) and then digested by DNase (Eurogentec, Belgium). No DNA contamination was observed after DNase digestion as detected by PCR of the digested product. APOE mRNAs were amplified by RT-PCR and allele quantitation was performed as described previously (9) by measuring a ratio of expression of two alleles in heterozygotes in order to avoid problems due to post-mortem delay, agonal state and cell population density.
Statistical analysis
The SAS software release 6.10 was used (SAS Institute, Cary, NC). Univariate analysis was performed using Pearson's χ 2 test. In the multivariate analysis, we coded the genotypes of each subject as dummy variables according to the tested hypotheses (at least one Th1/E47cs T allele: TT+TG/GG, at least one -491 T allele: TT+AT/AA and at least one ε4 allele). The effects of these variables on the disease were assessed with a multiple logistic regression model adjusted for age and gender. Comparison of the allelic expression was performed using Wilcoxon test.
We calculated the expected range of values of ε4 percentage in ε2ε4 AD and control individuals using the extreme values obtained for the ε2 and the ε4 percentages in the ε3ε4 and ε2ε3
